Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Haruka Momose is active.

Publication


Featured researches published by Haruka Momose.


Blood | 2009

Identification of cancer stem cells in a Tax-transgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma

Jumpei Yamazaki; Takuo Mizukami; Kazuya Takizawa; Madoka Kuramitsu; Haruka Momose; Atsuko Masumi; Yasushi Ami; Hideki Hasegawa; William W. Hall; Hajime Tsujimoto; Isao Hamaguchi; Kazunari Yamaguchi

Adult T-cell leukemia/lymphoma (ATL) is a malignant lymphoproliferative disorder caused by HTLV-I infection. In ATL, chemotherapeutic responses are generally poor, which has suggested the existence of chemotherapy-resistant cancer stem cells (CSCs). To identify CSC candidates in ATL, we have focused on a Tax transgenic mouse (Tax-Tg) model, which reproduces ATL-like disease both in Tax-Tg animals and also after transfer of Tax-Tg splenic lymphomatous cells (SLCs) to nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice. Using a limiting dilution transplantation, it was estimated that one CSC existed per 10(4) SLCs (0.01%). In agreement with this, we have successfully identified candidate CSCs in a side population (0.06%), which overlapped with a minor population of CD38(-)/CD71(-)/CD117(+) cells (0.03%). Whereas lymphoma did not develop after transplantation of 10(2) SLCs, 10(2) CSCs could consistently regenerate the original lymphoma. In addition, lymphoma and CSCs could also be demonstrated in the bone marrow and CD117(+) CSCs were observed in both osteoblastic and vascular niches. In the CSCs, Tax, Notch1, and Bmi1 expression was down-regulated, suggesting that the CSCs were derived from Pro-T cells or early hematopoietic progenitor cells. Taken together, our data demonstrate that CSCs certainly exist and have the potential to regenerate lymphoma in our mouse model.


Blood | 2012

Extensive gene deletions in Japanese patients with Diamond-Blackfan anemia

Madoka Kuramitsu; Aiko Sato-Otsubo; Tomohiro Morio; Masatoshi Takagi; Tsutomu Toki; Kiminori Terui; RuNan Wang; Hitoshi Kanno; Shouichi Ohga; Akira Ohara; Seiji Kojima; Toshiyuki Kitoh; Kumiko Goi; Kazuko Kudo; Tadashi Matsubayashi; Nobuo Mizue; Michio Ozeki; Atsuko Masumi; Haruka Momose; Kazuya Takizawa; Takuo Mizukami; Kazunari Yamaguchi; Seishi Ogawa; Etsuro Ito; Isao Hamaguchi

Fifty percent of Diamond-Blackfan anemia (DBA) patients possess mutations in genes coding for ribosomal proteins (RPs). To identify new mutations, we investigated large deletions in the RP genes RPL5, RPL11, RPL35A, RPS7, RPS10, RPS17, RPS19, RPS24, and RPS26. We developed an easy method based on quantitative-PCR in which the threshold cycle correlates to gene copy number. Using this approach, we were able to diagnose 7 of 27 Japanese patients (25.9%) possessing mutations that were not detected by sequencing. Among these large deletions, similar results were obtained with 6 of 7 patients screened with a single nucleotide polymorphism array. We found an extensive intragenic deletion in RPS19, including exons 1-3. We also found 1 proband with an RPL5 deletion, 1 patient with an RPL35A deletion, 3 with RPS17 deletions, and 1 with an RPS19 deletion. In particular, the large deletions in the RPL5 and RPS17 alleles are novel. All patients with a large deletion had a growth retardation phenotype. Our data suggest that large deletions in RP genes comprise a sizable fraction of DBA patients in Japan. In addition, our novel approach may become a useful tool for screening gene copy numbers of known DBA genes.


Journal of Biochemistry | 2009

Blockage by SP600125 of Fcε Receptor-Induced Degranulation and Cytokine Gene Expression in Mast Cells is Mediated Through Inhibition of Phosphatidylinositol 3-Kinase Signalling Pathway

Shuhei Tanemura; Haruka Momose; Nao Shimizu; Daiju Kitagawa; Jungwon Seo; Tokiwa Yamasaki; Kentaro Nakagawa; Hiroaki Kajiho; Josef M. Penninger; Toshiaki Katada; Hiroshi Nishina

SP600125 is used as a specific inhibitor of c-Jun N-terminal kinase (JNK). We initially aimed to examine physiological roles of JNK in mast cells that play a central role in inflammatory and immediate allergic responses. We found that Fc receptor for IgE (FcepsilonRI)-induced degranulation (serotonin release) and cytokine gene expression [interleukin (IL)-6, tumour necrosis factor-alpha and IL-13] in bone marrow-derived mast cells, were almost completely inhibited by SP600125. However, the time course of FcepsilonRI-induced JNK activation did not correlate with that of serotonin release. Furthermore, FcepsilonRI-induced degranulation and cytokine gene expression were not impaired in a JNK activator, MKK7-deficient mast cells, in which JNK activation was lost. These results indicate that the inhibitory effects by SP600125 are not due to impaired JNK activation. Instead, we found that SP600125 markedly inhibited the FcepsilonRI-induced activation of phosphatidylinositol 3-kinase (PI3K) and Akt, the same as a PI3K inhibitor, wortmannin. Finally, we found that SP600125 specifically inhibits delta form of p110 catalytic subunit (p110delta) of PI3K. Thus, SP600125 exerts its influence on mast cell functions by inhibiting the kinase activity of PI3K, but not JNK.


Vaccine | 2008

Application of DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation

Takuo Mizukami; Jun-ichi Imai; Isao Hamaguchi; Mika Kawamura; Haruka Momose; Seishiro Naito; Jun-ichi Maeyama; Atsuko Masumi; Madoka Kuramitsu; Kazuya Takizawa; Nobuo Nomura; Shinya Watanabe; Kazunari Yamaguchi

We propose that DNA microarray analysis can be used in the quality control of pandemic and endemic influenza vaccine. Based on the expression profiles of 76 genes in the rat lung one day after inoculation of influenza vaccine, we can distinguish whole-virion influenza vaccine (PDv: pandemic influenza vaccine and WPv: whole virion-particle vaccine) and sub-virion vaccine (HA vaccine) from saline. Among these 76 genes, we found genes up-regulated by influenza infection, as well as genes involved in the immune response, and interferon. Hierarchical clustering of each influenza vaccine by the expression profiles of these 76 genes matched data from current quality control tests in Japan, such as the abnormal toxicity test (ATT) and the leukopenic toxicity test (LTT). Thus, it can be concluded that DNA microarray technology is an informative, rapid and highly sensitive method with which to evaluate the quality of influenza vaccines. Using DNA microarray system, consistent with the results of the ATT and LTT, it was clarified that there was no difference in vaccine quality between PDv and WPv.


British Journal of Haematology | 2008

Deficient RPS19 protein production induces cell cycle arrest in erythroid progenitor cells.

Madoka Kuramitsu; Isao Hamaguchi; Mizukami Takuo; Atsuko Masumi; Haruka Momose; Kazuya Takizawa; Masayo Mochizuki; Seishirou Naito; Kazunari Yamaguchi

The gene encoding ribosomal protein S19 (RPS19) is one of the responsible genes for Diamond‐Blackfan anaemia (DBA), a congenital erythroblastopenia. Although haplo‐insufficiency of RPS19 has been suggested to be the onset mechanism underlying the pathogenesis of DBA, the sequential mechanism has not been elucidated. In order to analyse the consequences of the missense mutation of RPS19 specific for DBA patients, we made mutated RPS19 expression vectors. Twelve C‐terminally Flag‐tagged missense mutants were exogenously expressed from retroviral vectors and analysed by Western blot analysis and flow cytometry. When these 12 mutants were expressed in the erythro‐leukaemic cell lines K562 and human bone marrow CD34+ cells, almost all of the mutant proteins (except for G120R) were unstable, and the levels of mutated RPS19 protein were significantly low. To address the effect of deficient RPS19 expression on cell proliferation, RPS19 was downregulated by siRNA. Repressive expression of RPS19 in human CD34+ cells produced an elevated number of cells at G0 and induced erythroid progenitor‐specific defects in BM cells. These results suggest that abnormal ribosomal biogenesis causes inadequate cell cycle arrest in haematopoietic progenitors, and that, subsequently, erythroid progenitors are specifically hampered. These in vitro phenotypes of genetically manipulated CD34+ cells mimic DBA pathogenesis.


Journal of Interferon and Cytokine Research | 2010

Possible Recruitment of Peripheral Blood CXCR3+ CD27+ CD19+ B Cells to the Liver of Chronic Hepatitis C Patients

Toshiaki Mizuochi; Masahiko Ito; Koji Saito; Michiyuki Kasai; Toshiaki Kunimura; Toshio Morohoshi; Haruka Momose; Isao Hamaguchi; Kenji Takai; Shiro Iino; Miho Suzuki; Satoshi Mochida; Kenji Ikebuchi; Kazunari Yamaguchi

It has been suggested that hepatitis C virus (HCV) infects not only hepatocytes but also immune cells, including B cells. HCV infection of B cells is the likely cause of B-cell dysregulation disorders such as mixed cryoglobulinemia, rheumatoid factor production, and B-cell lymphoproliferative disorders that may evolve into non-Hodgkins lymphoma. To clarify the effects of chronic HCV infection on B-cell dynamics, peripheral B cells from chronic hepatitis C patients (CHC) were characterized. We found that the frequency of CD27(+) B cells, that is memory phenotype, was significantly reduced in the peripheral blood of CHC. At the same time, the amount of IFN-gamma-inducible protein-10 (IP-10), a CXCR3 ligand, was markedly elevated in the plasma of CHC. Furthermore, the CD27(+) B-cell population was found to highly express CXCR3 in CHC, thus suggesting that the CD27(+) B-cell population was recruited from peripheral blood to the inflammatory site of the liver of CHC, where IP-10 is produced. Immunohistochemical analyses of intrahepatic lymphocytes indicated that CXCR3(+) B cells were infiltrated in the liver of CHC. Our results thus offer new insight into the role of memory B cells in the HCV pathogenesis.


Journal of Clinical Microbiology | 2015

Identification of TL-Om1, an Adult T-Cell Leukemia (ATL) Cell Line, as Reference Material for Quantitative PCR for Human T-Lymphotropic Virus 1

Madoka Kuramitsu; Kazu Okuma; Makoto Yamagishi; Tadanori Yamochi; Sanaz Firouzi; Haruka Momose; Takuo Mizukami; Kazuya Takizawa; Kumiko Araki; Kazuo Sugamura; Kazunari Yamaguchi; Toshiki Watanabe; Isao Hamaguchi

ABSTRACT Quantitative PCR (qPCR) for human T-lymphotropic virus 1 (HTLV-1) is useful for measuring the amount of integrated HTLV-1 proviral DNA in peripheral blood mononuclear cells. Many laboratories in Japan have developed different HTLV-1 qPCR methods. However, when six independent laboratories analyzed the proviral load of the same samples, there was a 5-fold difference in their results. To standardize HTLV-1 qPCR, preparation of a well-defined reference material is needed. We analyzed the integrated HTLV-1 genome and the internal control (IC) genes of TL-Om1, a cell line derived from adult T-cell leukemia, to confirm its suitability as a reference material for HTLV-1 qPCR. Fluorescent in situ hybridization (FISH) showed that HTLV-1 provirus was monoclonally integrated in chromosome 1 at the site of 1p13 in the TL-Om1 genome. HTLV-1 proviral genome was not transferred from TL-Om1 to an uninfected T-cell line, suggesting that the HTLV-1 proviral copy number in TL-Om1 cells is stable. To determine the copy number of HTLV-1 provirus and IC genes in TL-Om1 cells, we used FISH, digital PCR, and qPCR. HTLV-1 copy numbers obtained by these three methods were similar, suggesting that their results were accurate. Also, the ratio of the copy number of HTLV-1 provirus to one of the IC genes, RNase P, was consistent for all three methods. These findings indicate that TL-Om1 cells are an appropriate reference material for HTLV-1 qPCR.


FEBS Letters | 2009

Interferon regulatory factor‐2 induces megakaryopoiesis in mouse bone marrow hematopoietic cells

Atsuko Masumi; Isao Hamaguchi; Madoka Kuramitsu; Takuo Mizukami; Kazuya Takizawa; Haruka Momose; Seishiro Naito; Kazunari Yamaguchi

Megakaryopoiesis is associated with inflammatory reactions. To investigate the role of interferon regulatory factors (IRFs) in inflammation‐associated megakaryopoiesis, mouse bone marrow hematopoietic stem cells (HSCs) were analyzed. IFN‐γ treatment induced IRF‐2 expression as well as the expression of CD41 and IRF‐1 in HSCs. An in vitro clonogenic assay showed that IRF‐2‐ but not IRF‐1‐overexpressing cells increased the number of megakaryocytic colonies. IRF‐2 transfection up‐regulated CD41 promoter activity in hematopoietic cell lines. The number of CD41‐positive bone marrow cells increased in mice injected with IRF‐2‐expressing bone marrow cells. These findings suggest that IRF‐2 plays an important role in megakaryopoiesis in inflammatory states.


Vaccine | 2008

Application of quantitative gene expression analysis for pertussis vaccine safety control.

Isao Hamaguchi; Jun-ichi Imai; Haruka Momose; Mika Kawamura; Takuo Mizukami; Seishiro Naito; Jun-ichi Maeyama; Atsuko Masumi; Madoka Kuramitsu; Kazuya Takizawa; Hiroshi Kato; Tetsuya Mizutani; Yoshinobu Horiuchi; Nobuo Nomura; Shinya Watanabe; Kazunari Yamaguchi

Although vaccines are routinely used to prevent infectious diseases, little is known about the comprehensive influences caused by vaccines. In this study, we showed, using comprehensive gene expression analysis, that pertussis vaccine affected many genes in multiple organs of vaccine-treated animals. In particular, lung was revealed to be the most suitable target to evaluate pertussis vaccine toxicity. The 13 genes identified from the analysis of vaccine-treated lung at day 1 showed a clear dendrogram corresponding to pertussis vaccine toxicity. Furthermore, quantitative analysis of these genes revealed a positive correlation between their respective expression levels and the degree of toxic effects observed in samples that had been treated with various doses of reference pertussis vaccines. The quantification of this 13 gene-set is an indicator of the vaccine toxicity-related reaction.


PLOS ONE | 2014

System Vaccinology for the Evaluation of Influenza Vaccine Safety by Multiplex Gene Detection of Novel Biomarkers in a Preclinical Study and Batch Release Test

Takuo Mizukami; Haruka Momose; Madoka Kuramitsu; Kazuya Takizawa; Kumiko Araki; Keiko Furuhata; Ken J. Ishii; Isao Hamaguchi; Kazunari Yamaguchi

Vaccines are beneficial and universal tools to prevent infectious disease. Thus, safety of vaccines is strictly evaluated in the preclinical phase of trials and every vaccine batch must be tested by the National Control Laboratories according to the guidelines published by each country. Despite many vaccine production platforms and methods, animal testing for safety evaluation is unchanged thus far. We recently developed a systems biological approach to vaccine safety evaluation where identification of specific biomarkers in a rat pre-clinical study evaluated the safety of vaccines for pandemic H5N1 influenza including Irf7, Lgals9, Lgalsbp3, Cxcl11, Timp1, Tap2, Psmb9, Psme1, Tapbp, C2, Csf1, Mx2, Zbp1, Ifrd1, Trafd1, Cxcl9, β2m, Npc1, Ngfr and Ifi47. The current study evaluated whether these 20 biomarkers could evaluate the safety, batch-to-batch and manufacturer-to-manufacturer consistency of seasonal trivalent influenza vaccine using a multiplex gene detection system. When we evaluated the influenza HA vaccine (HAv) from four different manufactures, the biomarker analysis correlated to findings from conventional animal use tests, such as abnormal toxicity test. In addition, sensitivity of toxicity detection and differences in HAvs were higher and more accurate than with conventional methods. Despite a slight decrease in body weight caused by HAv from manufacturer B that was not statistically significant, our results suggest that HAv from manufacturer B is significantly different than the other HAvs tested with regard to Lgals3bp, Tapbp, Lgals9, Irf7 and C2 gene expression in rat lungs. Using the biomarkers confirmed in this study, we predicted batch-to-batch consistency and safety of influenza vaccines within 2 days compared with the conventional safety test, which takes longer. These biomarkers will facilitate the future development of new influenza vaccines and provide an opportunity to develop in vitro methods of evaluating batch-to-batch consistency and vaccine safety as an alternative to animal testing.

Collaboration


Dive into the Haruka Momose's collaboration.

Top Co-Authors

Avatar

Isao Hamaguchi

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Takuo Mizukami

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Madoka Kuramitsu

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Kazunari Yamaguchi

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Kazuya Takizawa

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Atsuko Masumi

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Keiko Furuhata

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Seishiro Naito

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge